178 related articles for article (PubMed ID: 38758372)
1. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
Yin X; Liu X; Ren F; Meng X
Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
Zhou B; Gong Q; Li B; Qie HL; Li W; Jiang HT; Li HF
J Clin Pharm Ther; 2022 May; 47(5):643-651. PubMed ID: 35023208
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.
Zhang B; Liu H; Shi C; Gao Z; Zhong R; Gu A; Chu T; Wang H; Xiong L; Zhang W; Zhang X; Yan B; Teng J; Wang W; Bai H; Qiao R; Cheng L; Kuang Y; Zhao R; Zhong H; Han B
BMC Cancer; 2024 Jun; 24(1):715. PubMed ID: 38862908
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
7. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
9. Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy.
Yu L; Hu Y; Xu J; Qiao R; Zhong H; Han B; Xia J; Zhong R
Int J Cancer; 2023 Aug; 153(3):635-643. PubMed ID: 37078587
[TBL] [Abstract][Full Text] [Related]
10. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M
Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495
[TBL] [Abstract][Full Text] [Related]
12. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of chemo-free therapy in epidermal growth factor receptor tyrosine kinase inhibitor-resistant advanced non-small cell lung cancer: A single-arm, phase II study.
Zhang S; Yang L; Yang Y; Yang G; Xu H; Niu X; Wang Y
Cancer Med; 2023 Oct; 12(19):19438-19448. PubMed ID: 37723846
[TBL] [Abstract][Full Text] [Related]
14. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in
Isomoto K; Haratani K; Hayashi H; Shimizu S; Tomida S; Niwa T; Yokoyama T; Fukuda Y; Chiba Y; Kato R; Tanizaki J; Tanaka K; Takeda M; Ogura T; Ishida T; Ito A; Nakagawa K
Clin Cancer Res; 2020 Apr; 26(8):2037-2046. PubMed ID: 31937613
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
Front Immunol; 2021; 12():731546. PubMed ID: 34484242
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of immune checkpoint inhibitors in advanced
Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
Front Immunol; 2022; 13():975246. PubMed ID: 36159795
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity in PD-L1 expression between primary and metastatic lymph nodes: a predictor of EGFR-TKI therapy response in non-small cell lung cancer.
Hu Y; Zhang Y; Lu Y; Xu Y; Xu J; Zhong H; Cheng L; Zhong R
Respir Res; 2024 Jun; 25(1):233. PubMed ID: 38840238
[TBL] [Abstract][Full Text] [Related]
19. Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial.
Pu X; Xiao Z; Li J; Wu Z; Ma Z; Weng J; Xiao M; Chen Y; Cao Y; Cao P; Wang Q; Xu Y; Li K; Chen B; Xu F; Liu L; Kong Y; Zhang H; Duan H; Wu L
Lung Cancer; 2024 May; 191():107538. PubMed ID: 38552544
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study.
Wang W; Shao L; Xu Y; Song Z; Lou G; Zhang Y; Chen M
BMC Pulm Med; 2022 May; 22(1):179. PubMed ID: 35524294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
